Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
KymriahⓇ
-
CAR-T therapy
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT03568461 ELARA (CCTL019E2202)
Relapsed/refractory follicular lymphoma (FL)
Phase 2
97
Complete Response Rate (CRR)
Single-arm study of tisagenlecleucel
Adult patients with relapsed or refractory FL
H1-2021 (actual)
Schuster, et al. presented at ASCO, EHA and ICML 2021
NCT03570892 BELINDA (CCTL019H2301)
2nd line Diffuse large B-cell lymphoma (DLBCL)
Phase 3
318
Event-free Survival (EFS)
Tisagenlecleucel versus standard of care
Adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of
rituximab and anthracycline- containing frontline immunochemotherapy
H2-2021
Bishop et al at SITC 2019
Abstract submission to congress in H2-2021
105 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation